Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 4, 2005, Pages 637-642

  Köksal, Aydin Ş ^a,c   Parlak, Erkan ^a   Filik, Levent ^a   Yolcu, Ömer F ^a   Ödemiş, Bülent ^a   Ülker, Aysel ^a   Şaşmaz, Nurgül ^a   Özden, Ali ^b   Şahin, Burhan ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Amoxicillin; Clarithromycin; Helicobacter pylori; Metronidazole; Ranitidine bismuth citrate; Second line therapy; Tetracycline

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; FATIGUE; FECES COLOR; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROSCOPY; GLOSSITIS; HEADACHE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SECOND LINE THERAPY; SIDE EFFECT; STOMACH ULCER; TASTE DISORDER; TREATMENT OUTCOME; TURKEY (REPUBLIC); UREA BREATH TEST; VOMITING; XEROSTOMIA;

EID: 19944384245     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03801.x     Document Type: Article

References (33)

1. Tytgat GNJ. Treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment. Pharmacol. Ther. 1994; 8: 358-68.
2. Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-42.
3. Wong BCY, Lam SK, Lai KC et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment. Pharmacol. Ther. 1999; 13: 303-9.
4. Bayerdörffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 345: 1591-4.
5. Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig. Dis. 2001; 19: 134-43.
6. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 2002; 16: 167-80.
7. Gomollón F, Ducons CA, Ferrero M et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999; 4: 22-5.
8. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment. Pharrmacol. Ther. 1999; 13: 1311-16.
9. Perri F, Festa V, Clemente R et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. 2001; 96: 58-62.
10. Rinaldi V, Zullo A, De Francesco V et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment. Pharmacol. Ther. 1999; 13: 163-8.
11. Zullo A, Hassan C, Campo SM et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment. Pharmacol. Ther. 2001; 15: 1193-7.
12. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand. J. Gastroenterol. 2001; 36: 690-700.
13. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am. J. Gastroenterol. 2001; 96: 1335-9.
14. Goddard AF, Logan RP. Urea breath tests for detecting Helicobacter pylori. Aliment. Pharmacol. Ther. 1997; 11: 641-9.
15. Güliter S, Keleş H, Kolukisa E, Canver B. Lansoprazol+klaritromisin+amoksisilin tedavi rejiminin ilk basamak Helikobakter pylori eradikasyonundaki yeri (Abstract). Turk. J. Gastroenterol. 2003; 14 (Suppl. 1): S149.
16. Önder GF, Aydin A, Avşargil B, Akarca U, Tunçyü rek M, Özütemiz Ö. Helikobakter pylori infeksiyonunda pantoprazol, amoksisilin, klaritromisin (PAK) kombinasyonu ile 1 ve 2 haftalik tedavilerin etkinliǧi (Abstract). Turk. J. Gastroenterol. 2003; 14 (Suppl. 1): S157.
17. Houben MH, Van Der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy: the impact of antimicrobial resistance on eradication rates. Aliment. Pharmacol. Ther. 1999; 13: 1047-55.
18. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. 2000; 45: 68-76.
19. Kantarçeken B, Yildirim B, Aladaǧ M, Karincaoǧlu M, Hilmioǧlu F. Helikobakter pylori ve antibiyotik direnci (Abstract). Turk. J. Gastroenterol. 1998; 9 (Suppl. 1): S1.
20. Işiksal F, Çolakoǧlu S, Köksal F, Polat E, Yetgin M. Helikobakter pylori-antibiyotik direnci (Abstract). Turk. J. Gastroenterol. 2003; 14 (Suppl. 1): S40.
21. Çirak MY, Ünal S, Türet S et al. Helikobakter pylori'de klaritromisin direncinin genetik olarak belirlenmesi (Abstract). Turk. J. Gastroenterol. 2003; 14 (Suppl. 1): S6.
22. Huang JQ, Hunt RH. Are one week anti-H. pylori treatments more effective in patients with peptic ulcer disease (PUD) than in those with non-ulcer dyspepsia (NUD)? A meta-analysis. Am. J. Gastroenterol. 1998; 93: 1639.
23. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur. J. Gastroenterol. Hepatol. 2001; 13: 1303-7.
24. De Boer WA, Tytgat GNJ. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur. J. Gastroenterol. Hepatol. 2001; 13: 1281-4.
25. Van Doorn LJ, Figueriedo C, Sanna R et al. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 1998; 115: 58-66.
26. Nagahara A, Miwa H, Okhura R et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2001; 16: 613-18.
27. Gisbert JP, Marcos S, Gisbert JL et al. Rescue therapy after H. pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole (Abstract). Gastroenterology 1999; 116: 172.
28. McColm AA, McLaren A, Klingert G et al. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physicochemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. Aliment. Pharmacol. Ther. 1996; 10: 241-50.
29. Megraud F, Roberts P, Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter 2000; 5: 222-6.
30. van der Wouden EJ, Thijs JC, van Zwet AA, Kooy A, Kliebeuker JH. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 1999; 13: 297-302.
31. Wong BCY, Wong WM, Wang WH et al. One-week ranitidine bismuth citrate-based triple therapy for eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. Aliment. Pharmacol. Ther. 2001; 15: 403-9.
32. Tursi A, Brandimarte G, Giorgetti G, Modeo ME, Gigliobianco A. Efficacy and tolerability of ranitidine bismuth citrate plus amoxicillin and clarithromycin as first-or second-line therapy to cure Helicobacter pylori infection. Hepatogastroenterology 2002; 49: 1006-9.
33. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment. Pharmacol. Ther. 2001; 15: 1017-22.